Study

EORTC-90091-10093

TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial)

Study documentation Back to result

Trial Status

All trial activities ended

Dates

Date of activation: 26-Apr-2013
Date Step1 close: 03-Oct-2016

Data management at EORTC

Yes

Design

Phase 2
Randomized open label

Targeted Sample size

EORTC Groups: 25 - All Groups: 174

Treatment

Study Staff

Type of cancer

Participating groups

Protocol summary

http://clinicaltrials.gov/study/NCT01548677

NCT number

NCT01548677

EudraCT

2009-017485-23